×
Welcome
to the Antibody Engineering Lab
Frederico Aires da Silva

Research Overview

The FAS Lab is located in the beautiful city of Lisbon, Portugal. Our antibody engineering research group is affiliated with the Microbiology and Immunology Lab at the Centre for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon. We apply rational design and molecular evolution approaches – such as in vivo phage display selections, functional screenings and next generation sequencing analysis – to develop future generations of therapeutic antibodies.
Based on these integrated approaches, we aim to develop a new generation of “smart bomb antibodies” against challenging targets and unmet diseases. For this purpose, our lab is mainly working with antibody fragments (Fab and scFv) and single-domain antibodies (sdAbs) as therapeutic scaffolds in the areas of infectious diseases, cancer, and neurodegenerative disorders.
(read more)
NEWS
We will be attending PEGS Europe, in Barcelona next week!!!!

Next week Frederico Aires da Silva will be attending the PEGS Europe in Barcelona to present our work entitle “In Vivo Phage Display Selections and Rabbit Derived Single-Domain Antibodies as a Promising Platform to Develop Highly Specific and Potent Therapeutic Antibodies”.  Please meet Frederico to know more about our work.

Oct 22, 2021

(read more)
FASLAB receives new funding from the Gilead GENESE Program to develop a novel class of recombinant antibodies for the treatment and prevention of SARS-CoV-2 infection.

SARS-CoV-2 and the resulting disease, COVID-19, caused economic and global health crises. Vaccination is the main strategy to reduce its spread. However, with the emergence of new variants, new therapeutic strategies are urgently required. Thus, in this project, we aim to develop a novel class of neutralizing antibodies for the treatment and prevention of SARS-CoV-2 infection.

Dec 16, 2021

(read more)
We were selected as one of the finalists for this year´s Innovation Showcase in the Animal Health Innovation Showcase on June 22nd, Boston.

We will present our antibody platform to develop a new generation of antibody-drug conjugates for the cancer treatment of our pets. Thanks to this opportunity, we will pitch our SmarbAb solution to experts and investors aiming to catapult our start-up to deliver safer and more effective therapeutics for Animal Health. We look forward to meeting everyone in Boston the next week.

16 June 2022

(read more)